ea0029p1635 | Thyroid (non-cancer) | ICEECE2012
Pena V.
, Vicente A.
, Maqueda E.
, Sastre J.
, Val F Del
, Marco A.
, Luque I.
, Lopez J.
Background: One of the main drawbacks of primary treatment of Graves disease (GD) with thionamide drugs (TD) is the high relapse rate estimated to be 5060%. Fear about side effects, specially agranulocitosis and hepatic complications, is other drawback of this treatment option.Objective: To evaluate the clinical and/or biochemical characteristics that might predict relapse in patients with GD treated with TD.Design and ...